Skip to main content

Pharmacy

By Susan Morse | 10:53 am | December 29, 2022
The XBB variant, which is resistant to immunity, now makes up over half of cases in New England.
By Susan Morse | 10:35 am | December 21, 2022
The issue is one of demand, not supply, experts say.
By Jeff Lagasse | 03:02 pm | December 19, 2022
Overall, 51% of enrolled patients using Adstiladrin therapy achieved a complete response, with all signs of cancer disappearing.
By Jeff Lagasse | 02:41 pm | December 07, 2022
The companies hope the treatment will provide greater efficacy as the virus evolves and proves increasingly resistant to current therapies.
By Jeff Lagasse | 11:26 am | December 07, 2022
The company believes the equivalent therapies will lower healthcare costs while providing more choice and flexibility.
By Jeff Lagasse | 03:08 pm | December 06, 2022
The end result will be a "diversified pharmacy solutions organization" serving commercial markets and government programs.
By Jeff Lagasse | 11:44 am | December 06, 2022
The AHA recommended that the DEA release proposed rules for telehealth special registration as soon as possible.
By Jeff Lagasse | 03:35 pm | November 09, 2022
The AG's office alleges the PBM was paid for drugs for workers' compensation claims that were in excess of what's allowed under state law.
By Jeff Lagasse | 12:39 pm | November 09, 2022
Substitution of costly generics with lesser-cost ones could generate great savings, Johns Hopkins says.
By Jeff Lagasse | 12:13 pm | November 02, 2022
The vaccine demonstrated efficacy of almost 82% against severe RSV in infants from birth through the first 90 days of life.